CTOs on the Move

NightstaRx

www.nightstarx.com

 
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nightstarx.com
  • 81 Hartwell Ave Suite 100
    Lexington, MA USA 02421
  • Phone: +44 7817 868300

Executives

Name Title Contact Details

Funding

NightstaRx raised $45M on 06/30/2017

Similar Companies

ST CATHRINE REGINAL HOSP

Saint Catherine Medical Center Fountain Springs is committed to establishing itself as a center of clinical excellence, the preferred medical center for residents of our region and for physicians to practice, and the regional employer of choice. This

Tilray

Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents.

National Diabetic Pharmacies

National Diabetic Pharmacies is a Salem, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EndoSound

Transforming the economics, usability, and accessibility of Endoscopic Ultrasound (EUS) for the benefit of patients, physicians, and payers.

Aeon Biopharma

Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.